The impact of the United Kingdom (UK) Soft Drinks Industry Levy (SDIL) on childhood asthma hospital admission rates.
ArriVent’s lung cancer therapy gains FDA breakthrough status
The Phase III FURVENT trial of furmonertinib to treat first-line NSCLC with EGFR exon 20 insertion mutations is enrolling subjects. Credit: create jobs 51 /